Pfizer (NYSE:PFE - Get Free Report) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $2.80-3.00 for the period, compared to the consensus EPS estimate of $2.86. The company issued revenue guidance of $61-64 billion, compared to the consensus revenue estimate of $63.22 billion. Pfizer also updated its FY 2025 guidance to 2.800-3.000 EPS.
Pfizer Stock Up 4.6 %
PFE stock traded up $1.17 during mid-day trading on Tuesday, reaching $26.42. The company had a trading volume of 71,361,667 shares, compared to its average volume of 38,635,492. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a market capitalization of $149.72 billion, a price-to-earnings ratio of 35.49, a price-to-earnings-growth ratio of 0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a fifty day simple moving average of $27.09 and a 200 day simple moving average of $28.25.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. The company's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) EPS. Analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.
Pfizer Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.51%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 227.03%.
Analyst Upgrades and Downgrades
PFE has been the topic of several research analyst reports. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price target for the company. Guggenheim reduced their target price on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $32.15.
Read Our Latest Stock Report on PFE
Insider Activity at Pfizer
In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
